Introducing a simple and cost-effective RT-PCR protocol for detection of DPYD*2A polymorphism: the first study in Kurdish population

Vodenkova S, Buchler T, Cervena K, Veskrnova V, Vodicka P, Vymetalkova V (2020) 5-fluorouracil and other fluoropyrimidines in colorectal cancer: past, present and future. Pharmacol Ther 206:107447. https://doi.org/10.1016/j.pharmthera.2019.107447

CAS  Article  PubMed  Google Scholar 

Knikman JE, Gelderblom H, Beijnen JH, Cats A, Guchelaar HJ, Henricks LM (2021) Individualized dosing of fluoropyrimidine-based chemotherapy to prevent severe fluoropyrimidine-related toxicity: what are the options? Clin Pharmacol Ther 109(3):591–604. https://doi.org/10.1002/cpt.2069

CAS  Article  PubMed  Google Scholar 

Meulendijks D, Henricks LM, Jacobs BAW, Aliev A, Deenen MJ, de Vries N, Rosing H, van Werkhoven E, de Boer A, Beijnen JH, Mandigers C, Soesan M, Cats A, Schellens JHM (2017) Pretreatment serum uracil concentration as a predictor of severe and fatal fluoropyrimidine-associated toxicity. Br J Cancer 116(11):1415–1424. https://doi.org/10.1038/bjc.2017.94

CAS  Article  PubMed  PubMed Central  Google Scholar 

Meulendijks D, Henricks LM, Sonke GS, Deenen MJ, Froehlich TK, Amstutz U, Largiader CR, Jennings BA, Marinaki AM, Sanderson JD, Kleibl Z, Kleiblova P, Schwab M, Zanger UM, Palles C, Tomlinson I, Gross E, van Kuilenburg AB, Punt CJ, Koopman M, Beijnen JH, Cats A, Schellens JH (2015) Clinical relevance of DPYD as variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 16(16):1639–1650. https://doi.org/10.1016/S1470-2045(15)00286-7

CAS  Article  PubMed  Google Scholar 

Dolat M, Macaire P, Goirand F, Vincent J, Hennequin A, Palmier R, Bengrine-Lefevre L, Ghiringhelli F, Royer B, Schmitt A (2020) Association of 5-FU therapeutic drug monitoring to DPD phenotype assessment may reduce 5-FU under-exposure. Pharmaceuticals (Basel). https://doi.org/10.3390/ph13110416

Article  Google Scholar 

Wigle TJ, Povitz BL, Medwid S, Teft WA, Legan RM, Lenehan J, Nevison S, Panuganty V, Keller D, Mailloux J, Siebring V, Sarma S, Choi YH, Welch S, Winquist E, Schwarz UI, Kim RB (2021) Impact of pretreatment dihydropyrimidine dehydrogenase genotype-guided fluoropyrimidine dosing on chemotherapy associated adverse events. Clin Transl Sci 14(4):1338–1348. https://doi.org/10.1111/cts.12981

CAS  Article  PubMed  PubMed Central  Google Scholar 

Lee JJ, Beumer JH, Chu E (2016) Therapeutic drug monitoring of 5-fluorouracil. Cancer Chemother Pharmacol 78(3):447–464. https://doi.org/10.1007/s00280-016-3054-2

CAS  Article  PubMed  PubMed Central  Google Scholar 

Garcia-Alfonso P, Saiz-Rodriguez M, Mondejar R, Salazar J, Paez D, Borobia AM, Safont MJ, Garcia-Garcia I, Colomer R, Garcia-Gonzalez X, Herrero MJ, Lopez-Fernandez LA, Abad-Santos F (2022) Consensus of experts from the Spanish pharmacogenetics and pharmacogenomics society and the Spanish society of medical oncology for the genotyping of DPYD in cancer patients who are candidates for treatment with fluoropyrimidines. Clin Transl Oncol 24(3):483–494. https://doi.org/10.1007/s12094-021-02708-4

CAS  Article  PubMed  Google Scholar 

Wei X, Elizondo G, Sapone A, McLeod HL, Raunio H, Fernandez-Salguero P, Gonzalez FJ (1998) Characterization of the human dihydropyrimidine dehydrogenase gene. Genomics 51(3):391–400. https://doi.org/10.1006/geno.1998.5379

CAS  Article  PubMed  Google Scholar 

Sharma BB, Rai K, Blunt H, Zhao W, Tosteson TD, Brooks GA (2021) Pathogenic DPYD variants and treatment-related mortality in patients receiving fluoropyrimidine chemotherapy: a systematic review and meta-analysis. Oncologist 26(12):1008–1016. https://doi.org/10.1002/onco.13967

CAS  Article  PubMed  PubMed Central  Google Scholar 

Henricks LM, Opdam FL, Beijnen JH, Cats A, Schellens JHM (2017) DPYD genotype-guided dose individualization to improve patient safety of fluoropyrimidine therapy: call for a drug label update. Ann Oncol 28(12):2915–2922. https://doi.org/10.1093/annonc/mdx411

CAS  Article  PubMed  Google Scholar 

Iachetta F, Bonelli C, Romagnani A, Zamponi R, Tofani L, Farnetti E, Nicoli D, Damato A, Banzi M, Casali B, Pinto C (2019) The clinical relevance of multiple DPYD polymorphisms on patients candidate for fluoropyrimidine based-chemotherapy an Italian case-control study. Br J Cancer 120(8):834–839. https://doi.org/10.1038/s41416-019-0423-8

CAS  Article  PubMed  PubMed Central  Google Scholar 

Amstutz U, Henricks LM, Offer SM, Barbarino J, Schellens JHM, Swen JJ, Klein TE, McLeod HL, Caudle KE, Diasio RB, Schwab M (2018) Clinical pharmacogenetics implementation consortium (CPIC) guideline for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing: 2017 update. Clin Pharmacol Ther 103(2):210–216. https://doi.org/10.1002/cpt.911

CAS  Article  PubMed  Google Scholar 

Henricks LM, Lunenburg CA, Meulendijks D, Gelderblom H, Cats A, Swen JJ, Schellens JH, Guchelaar HJ (2015) Translating DPYD genotype into DPD phenotype: using the DPYD gene activity score. Pharmacogenomics 16(11):1277–1286. https://doi.org/10.2217/pgs.15.70

Article  PubMed  Google Scholar 

Henricks LM, van Merendonk LN, Meulendijks D, Deenen MJ, Beijnen JH, de Boer A, Cats A, Schellens JHM (2019) Effectiveness and safety of reduced-dose fluoropyrimidine therapy in patients carrying the DPYD*2A variant: a matched pair analysis. Int J Cancer 144(9):2347–2354. https://doi.org/10.1002/ijc.32022

CAS  Article  PubMed  Google Scholar 

Terrazzino S, Cargnin S, Del Re M, Danesi R, Canonico PL, Genazzani AA (2013) DPYD IVS14+1G>A and 2846A>T genotyping for the prediction of severe fluoropyrimidine-related toxicity: a meta-analysis. Pharmacogenomics 14(11):1255–1272. https://doi.org/10.2217/pgs.13.116

CAS  Article  PubMed  Google Scholar 

Maharjan AS, McMillin GA, Patel GK, Awan S, Taylor WR, Pai S, Frankel AE, Nelson C, Wang B, Hosein PJ, Singh AP, Khushman M (2019) The prevalence of DPYD*9A (c.85T>C) genotype and the genotype-phenotype correlation in patients with gastrointestinal malignancies treated with fluoropyrimidines: updated analysis. Clin Colorectal Cancer 18(3):e280–e286. https://doi.org/10.1016/j.clcc.2019.04.005

Article  PubMed  Google Scholar 

Negarandeh R, Salehifar E, Saghafi F, Jalali H, Janbabaei G, Abdhaghighi MJ, Nosrati A (2020) Evaluation of adverse effects of chemotherapy regimens of 5-fluoropyrimidines derivatives and their association with DPYD polymorphisms in colorectal cancer patients. BMC Cancer 20(1):560. https://doi.org/10.1186/s12885-020-06904-3

CAS  Article  PubMed  PubMed Central  Google Scholar 

Naushad SM, Hussain T, Alrokayan SA, Kutala VK (2021) Pharmacogenetic profiling of dihydropyrimidine dehydrogenase (DPYD) variants in the Indian population. J Gene Med 23(1):e3289. https://doi.org/10.1002/jgm.3289

CAS  Article  PubMed  Google Scholar 

Nie Q, Shrestha S, Tapper EE, Trogstad-Isaacson CS, Bouchonville KJ, Lee AM, Wu R, Jerde CR, Wang Z, Kubica PA, Offer SM, Diasio RB (2017) Quantitative contribution of rs75017182 to dihydropyrimidine dehydrogenase mRNA splicing and enzyme activity. Clin Pharmacol Ther 102(4):662–670. https://doi.org/10.1002/cpt.685

CAS  Article  PubMed  Google Scholar 

National Cancer Institute (2017) Common Terminology Criteria for Adverse Events (CTCAE), version 5.0. National Cancer Institute. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm. Accessed 2 Feb 2021

Heydarov R, Titov S, Abramov M, Timofeev E, Mikhailovich V (2017) Hydrogel microarray for detection of polymorphisms in the UGT1A1, DPYD, GSTP1 and ABCB1 genes. Cancer Biomark 18(3):265–272. https://doi.org/10.3233/CBM-160165

CAS  Article  PubMed  Google Scholar 

Deenen MJ, Meulendijks D, Cats A, Sechterberger MK, Severens JL, Boot H, Smits PH, Rosing H, Mandigers CM, Soesan M, Beijnen JH, Schellens JH (2016) Upfront genotyping of DPYD*2A to individualize fluoropyrimidine therapy: a safety and cost analysis. J Clin Oncol 34(3):227–234. https://doi.org/10.1200/JCO.2015.63.1325

CAS  Article  PubMed  Google Scholar 

Lunenburg C, van der Wouden CH, Nijenhuis M, Crommentuijn-van Rhenen MH, de Boer-Veger NJ, Buunk AM, Houwink EJF, Mulder H, Rongen GA, van Schaik RHN, van der Weide J, Wilffert B, Deneer VHM, Swen JJ, Guchelaar HJ (2020) Dutch pharmacogenetics working group (DPWG) guideline for the gene-drug interaction of DPYD and fluoropyrimidines. Eur J Hum Genet 28(4):508–517. https://doi.org/10.1038/s41431-019-0540-0

CAS  Article  PubMed  Google Scholar 

Abbasian MH, Ansarinejad N, Abbasi B, Iravani M, Ramim T, Hamedi F, Ardekani AM (2020) The role of dihydropyrimidine dehydrogenase and thymidylate synthase polymorphisms in fluoropyrimidine-based cancer chemotherapy in an iranian population. Avicenna J Med Biotechnol 12(3):157–164

PubMed  PubMed Central  Google Scholar 

Ruzzo A, Graziano F, Galli F, Galli F, Rulli E, Lonardi S, Ronzoni M, Massidda B, Zagonel V, Pella N, Mucciarini C, Labianca R, Ionta MT, Bagaloni I, Veltri E, Sozzi P, Barni S, Ricci V, Foltran L, Nicolini M, Biondi E, Bramati A, Turci D, Lazzarelli S, Verusio C, Bergamo F, Sobrero A, Frontini L, Menghi M, Magnani M (2017) Dihydropyrimidine dehydrogenase pharmacogenetics for predicting fluoropyrimidine-related toxicity in the randomised, phase III adjuvant TOSCA trial in high-risk colon cancer patients. Br J Cancer 117(9):1269–1277. https://doi.org/10.1038/bjc.2017.289

CAS  Article  PubMed  PubMed Central  Google Scholar 

Nahid NA, Apu MNH, Islam MR, Shabnaz S, Chowdhury SM, Ahmed MU, Nahar Z, Islam MS, Islam MS, Hasnat A (2018) DPYD*2A and MTHFR C677T predict toxicity and efficacy, respectively, in patients on chemotherapy with 5-fluorouracil for colorectal cancer. Cancer Chemother Pharmacol 81(1):119–129. https://doi.org/10.1007/s00280-017-3478-3

CAS  Article  PubMed  Google Scholar 

Amirfallah A, Kocal GC, Unal OU, Ellidokuz H, Oztop I, Basbinar Y (2018) DPYD, TYMS and MTHFR genes polymorphism frequencies in a series of Turkish colorectal cancer patients. J Pers Med. https://doi.org/10.3390/jpm8040045

Article  PubMed  PubMed Central  Google Scholar 

Jolivet C, Nassabein R, Soulieres D, Weng X, Amireault C, Ayoub JP, Beauregard P, Blais N, Carrier C, Cloutier AS, Desnoyers A, Lemay AS, Lemay F, Loungnarath R, Jolivet J, Letendre F, Tehfe M, Vadnais C, Viens D, Aubin F (2021) Implementing DPYD*2A genotyping in clinical practice: the Quebec, Canada. Experience Oncologist 26(4):e597–e602. https://doi.org/10.1002/onco.13626

CAS  Article  PubMed  Google Scholar 

Del Re M, Cinieri S, Michelucci A, Salvadori S, Loupakis F, Schirripa M, Cremolini C, Crucitta S, Barbara C, Di Leo A, Latiano TP, Pietrantonio F, Di Donato S, Simi P, Passardi A, De Braud F, Altavilla G, Zamagni C, Bordonaro R, Butera A, Maiello E, Pinto C, Falcone A, Mazzotti V, Morganti R, Danesi R (2019) DPYD*6 plays an important role in fluoropyrimidine toxicity in addition to DPYD*2A and c.2846A>T: a comprehensive analysis in 1254 patients. Pharmacogenomics J 19(6):556–563. https://doi.org/10.1038/s41397-019-0077-1

CAS  Article  PubMed  PubMed Central  Google Scholar 

Aboul-Soud MAM, Alzahrani AJ, Mahmoud A (2021) Decoding variants in drug-metabolizing enzymes and transporters in solid tumor patients by whole-exome sequencing. Saudi J Biol Sci 28(1):628–634. https://doi.org/10.1016/j.sjbs.2020.10.052

CAS 

留言 (0)

沒有登入
gif